HomeCompareGENE vs EPRT

GENE vs EPRT: Dividend Comparison 2026

GENE yields 261.44% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GENE wins by $612.74M in total portfolio value
10 years
GENE
GENE
● Live price
261.44%
Share price
$0.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$612.80M
Annual income
$349,686,678.74
Full GENE calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — GENE vs EPRT

📍 GENE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGENEEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GENE + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GENE pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GENE
Annual income on $10K today (after 15% tax)
$22,222.22/yr
After 10yr DRIP, annual income (after tax)
$297,233,676.93/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, GENE beats the other by $297,222,762.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GENE + EPRT for your $10,000?

GENE: 50%EPRT: 50%
100% EPRT50/50100% GENE
Portfolio after 10yr
$306.43M
Annual income
$174,849,759.73/yr
Blended yield
57.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

GENE
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
-24.5
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GENE buys
0
EPRT buys
0
No recent congressional trades found for GENE or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGENEEPRT
Forward yield261.44%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$612.80M$63.4K
Annual income after 10y$349,686,678.74$12,840.73
Total dividends collected$585.16M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellBuy

Year-by-year: GENE vs EPRT ($10,000, DRIP)

YearGENE PortfolioGENE Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$36,844$26,143.79$11,205$505.18+$25.6KGENE
2$129,445$90,022.09$12,672$682.46+$116.8KGENE
3$434,094$295,587.53$14,490$930.48+$419.6KGENE
4$1,390,885$926,404.44$16,786$1,282.69+$1.37MGENE
5$4,262,362$2,774,115.59$19,753$1,791.56+$4.24MGENE
6$12,505,839$7,945,111.88$23,677$2,541.64+$12.48MGENE
7$35,167,310$21,786,062.26$29,008$3,672.99+$35.14MGENE
8$94,885,057$57,256,035.19$36,463$5,425.08+$94.85MGENE
9$245,903,396$144,376,384.91$47,238$8,221.57+$245.86MGENE
10$612,803,313$349,686,678.74$63,385$12,840.73+$612.74MGENE

GENE vs EPRT: Complete Analysis 2026

GENEStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GENE Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this GENE vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GENE vs SCHDGENE vs JEPIGENE vs OGENE vs KOGENE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.